Nucleoside and Nucleotide reverse transcriptase inhibitors		Protease inhibitors
	Non-Nucleoside reverse transcriptase inhibitors		Fusion inhibitors
	HIV - 2		Integrase inhibitors

	Mutations associated with resistance	Mutations associated with « possible resistance »
IDV	M46I/L V82A/F/M/S/T [11] I84A/V [8] L90M and at least 2 mutations among : K20M/R, L24I, V32I, M36I, I54V/L/M/T, A71V/T, G73S/A, V77I	L90M
SQV/RTV 1000/100 mg BID	G48V At least 4 mutations among: L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M [9]	3 mutations among: L10F/I/M/R/V, I15A/V, K20I/M/R/T, L24I, I62V, G73S/T, V82A/F/S/T, I84V, L90M [9]
NFV	D30N I84A/V [8] N88S/D L90M	V82A/F/S/T and at least 2 mutations among: L10I, M36I, M46I/L, I54V/L/M/T, A71V/T, V77I [1]
fosAPV/RTV 700/100 mg BID	I50V V32I and I47A/V [2, 13, 14] At least 4 mutations among: L10F/I/V, L33F, M36I, I54A/L/M/S/T/V, I62V, V82A/C/F/G, I84V, L90M [2, 20]
LPV/r	At least 6 mutations among : L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M [3, 4, 5, 21] I47A [15, 16] L76V [18, 19]	4 or 5 mutations among: L10F/I/R/V, K20M/R, L24I, L33F, M46I/L, I50V, F53L, I54M/L/T/V, L63P, A71I/L/V/T, V82A/F/S/T, I84V, L90M [3, 4, 5, 21]
ATV/RTV 300/100 mg QD	I50L [6] At least  3 mutations among: L10F/I/V, G16E, L33F/I/V, M46I/L, D60E, I84V, I85V, L90M [7, 12, 22]
TPV/RTV 500/200 mg BID	At least a score of + 3* :  36I/L/V – 53L/W/Y + 58E + 69I/K/N/Q/R/Y + 89I/M/R/T/V [10, 23]	A score of + 2* : 36I/L/V – 53L/W/Y + 58E + 69I/K/N/Q/R/Y + 89I/M/R/T/V [10, 23]
DRV/RTV 600/100 mg BID	At least 4 mutations among: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V [17, 24, 25, 26]	3 mutations among: V11I, V32I, L33F, I47V, I50V, I54L/M, T74P, L76V, I84V, L89V [17, 24, 25, 26]

V82A is associated with better virological response to darunavir [27]

* Insufficient data for HIV-1 subtype non-B